Business Standard

Zydus Lifesciences Q4 net dips to 24% Rs 397 cr, revenue up 5%

Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures

Cadila Healthcare changes name to Zydus Lifesciences Limited
Premium

Vinay Umarji Ahmedabad
On the back of growth in domestic and emerging markets formulations businesses, Zydus Lifesciences Ltd. posted a net profit of Rs 397.4 crore for the fourth quarter ended March 31, 2022 of financial year 2021-22 (FY22).

The pharma major had reported a net profit of Rs 679 crore for the fourth quarter ended March 31, 2021 of the previous financial year 2020-21 (FY21).  However, when adjusted for one-time inventory provision, exceptional and non-recurring items as well as profit from discontinued operations, the net profit for Q4 of FY21 stood at Rs 525 crore.

Revenue from operations for the quarter grew

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 20 2022 | 6:30 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com